# Clinical application of acupuncture in the treatment of low anterior resection syndrome after rectal cancer surgery

Submission date	Recruitment status	[X] Prospectively registered
12/08/2022	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
16/08/2022	Completed	Results
Last Edited	Condition category	Individual participant data
09/05/2023	Digestive System	[] Record updated in last year

## Plain English summary of protocol

Background and study aims

Low anterior resection syndrome (LARS) is a collection of symptoms that people who have undergone a partial or total resection of the rectum might have. These symptoms include, for example, faecal incontinence or leakage, frequency or urgency of stools, loose stools, incomplete bowel movement, or tenesmus.

Through the patient-reported symptom scale and anorectal pressure test, the effectiveness of acupuncture in the treatment of low anterior resection syndrome for rectal cancer will be preliminarily evaluated, the details of the electroacupuncture intervention plan will be determined, and the onset time will be clarified.

This study will explore the feasibility of acupuncture treatment of low anterior resection syndrome for rectal cancer, and the attitudes, experiences, feelings and acceptance of different patients.

#### Who can participate?

Patients 18-75 years old who have undergone a partial or total resection of the rectum for cancer treatment.

#### What does the study involve?

Acupuncture at Baliao point 3 times a week for 4 weeks, a total of 12 times. In addition to acupuncture at Baliao point, the acupoints can be selected according to the patient's syndrome differentiation. For example, Shangjuxu and Xiajuxu will be selected for participants who have received radiotherapy. Also, Baihui and Changqiang will be selected for those who have had diarrhea for a long time.

After completing at least 4 weeks of treatment, 20 patients who are willing to cooperate with the interviews will be selected for semi-structured qualitative interviews.

## What are the possible benefits and risks of participating?

Benefit: The patients will receive electroacupuncture treatment and routine blood and urine routine, liver and kidney function, anorectal pressure (needed by some patients) examination for free, and a 300 yuan transportation subsidy will be given to the subjects after completing the

trial. It can improve the symptoms of low anterior resection syndrome to some extent, including improvement in unpredictable bowel function, emptying difficulties, altered stool consistency, urgency, increased stool frequency, incontinence, and repeated painful stool soiling. Potential risks: needle breakage after acupuncture, fainting, local skin infection, bleeding, hematoma, other systemic discomfort after acupuncture, etc.

Where is the study run from?
Third Affiliated Hospital of Beijing University of Chinese Medicine (China)

When is the study starting and how long is it expected to run for? March 2022 to June 2025

Who is funding the study?
Beijing Municipal Health Commission (China)

Who is the main contact? Dr Ming Yang yangming@bucm.edu.cn

## Contact information

## Type(s)

Scientific

#### Contact name

Dr Ming Yang

#### **ORCID ID**

http://orcid.org/0000-0002-2954-7435

#### Contact details

Floor 4,Comprehensive building No.51, Andingmen Outer Street Chaoyang District Beijing China 100029 +8613671273351 yangming@bucm.edu.cn

## Additional identifiers

## **EudraCT/CTIS** number

Nil known

**IRAS** number

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

CFH2022-4-7046

# Study information

#### Scientific Title

Clinical application of acupuncture in the treatment of low anterior resection syndrome after rectal cancer: an exploratory mixed methods research

### Acronym

**AFLARS** 

## Study objectives

To preliminarily evaluate the efficacy and the feasibility of acupuncture in the treatment of low anterior resection syndrome (LARS) for rectal cancer, and try to find a more convenient and effective treatment for LARS.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 22/07/2022, IRB of the Third Hospital Affiliated to Beijing University of Chinese Medicine (no. 51, Xiaoguan Street, Andingmenwai, Chaoyang District, Beijing, 100029, China; no telephone number provided; zydsyec@126.com), ref: BZYSY-2022KYKTPJ-07

## Study design

Mixed methods research including interventional single-arm clinical trial and semi-structured interviews

## Primary study design

Interventional

## Secondary study design

Non randomised study

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

No participant information sheet available

## Health condition(s) or problem(s) studied

Bowel function

#### **Interventions**

Current interventions, as of 09/05/2023:

This study is a mixed method study that includes an interventional single-arm clinical trial and semi-structured interviews. A 30 minutes electroacupuncture intervention at Baliao acupoints (BL31, BL 32, BL 33, BL 34) will be provided to participants three times per week for 4 weeks.

Semi-structured interviews will be conducted with 20 participants to understand patients' experience and feelings. The follow-up time points are 1, 3, and 6 months after the end of the 4-week treatment period.

#### Previous interventions:

This study is a mixed method study that includes an interventional single-arm clinical trial and semi-structured interviews. A 30 minutes electroacupuncture intervention at Baliao acupoints (BL31, BL 32, BL 33, BL 34) will be provided to participants two times per week for 8 weeks. The follow-up time points are 1, 3, and 6 months after the end of the 8-week treatment period.

### Intervention Type

Procedure/Surgery

## Primary outcome measure

Current primary outcome measure as of 09/05/2023:

Intestinal function is measured using a low anterior resection syndrome (LARS) score at baseline and once a week, 5 times in total.

(Low anterior resection syndrome (LARS) scale: refer to LARS scale, scoring the severity of urgency, frequency, clustering, incontinence for flatus and incontinence for liquid stool, 0-20 is classified as no LARS, 21-29 as mild, and 30-42 as severe)

#### Previous primary outcome measure:

Intestinal function is measured using a low anterior resection syndrome (LARS) score at baseline and once a week, 9 times in total.

(Low anterior resection syndrome (LARS) scale: refer to LARS scale, scoring the severity of urgency, frequency, clustering, incontinence for flatus and incontinence for liquid stool, 0-20 is classified as no LARS, 21-29 as mild, and 30-42 as severe)

#### Secondary outcome measures

Current secondary outcome measures as of 09/05/2023:

- 1. Intestinal function is measured using an MSKCC Bowel Function Instrument at baseline, and once a week, 5 times in total
- 2. Bowel functions are measured using anorectal manometry at baseline and after 12 acupuncture treatments
- 3. Quality of life is measured using an EQ-5D-5L instrument at baseline and every 2 weeks, 3 times in total
- 4. Quality of life is measured using an EORTC-QLQ-C30 instrument at baseline and every 4 weeks, twice in total

Previous secondary outcome measures:

- 1. Intestinal function is measured using an MSKCC Bowel Function Instrument at baseline, and once a week, 9 times in total
- 2. Bowel functions are measured using anorectal manometry at baseline and after 16 acupuncture treatments
- 3. Quality of life is measured using an EQ-5D-5L instrument at baseline and every 2 weeks, 5 times in total
- 4. Quality of life is measured using an EORTC-QLQ-C30 instrument at baseline and every 4 weeks, 3 times in total

## Overall study start date

10/03/2022

## Completion date

30/06/2025

# Eligibility

### Key inclusion criteria

Current inclusion criteria as of 09/05/2023:

Patients who are admitted to the outpatient or inpatient Department of Acupuncture, Moxibustion and Minimally Invasive Oncology, The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine, meet the following conditions:

- 1. Age 18-75 years old
- 2. Meet the LARS diagnostic criteria, and the LARS score is greater than 20
- 3. KPS score over 60 points, the expected survival time is more than 3 months
- 4. Have good communication and understanding skills, and be able to independently report outcome indicators and conduct qualitative interviews
- 5. Agree to participate in this study and sign the informed consent

## Previous inclusion criteria:

Patients who are admitted to the Outpatient Department of Acupuncture, Moxibustion and Minimally Invasive Oncology, The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine, meet the following conditions:

- 1. Age 18-75 years old
- 2. Meet the LARS diagnostic criteria, and the LARS score is greater than 20
- 3. KPS score over 60 points, the expected survival time is more than 3 months
- 4. Have good communication and understanding skills, and be able to independently report outcome indicators and conduct qualitative interviews
- 5. Agree to participate in this study and sign the informed consent

## Participant type(s)

Patient

## Age group

#### Adult

#### Lower age limit

18 Years

#### Upper age limit

75 Years

#### Sex

Both

## Target number of participants

60

## Key exclusion criteria

Current exclusion criteria as of 09/05/2023:

- 1. Those who have a history of other anorectal surgery or trauma affecting bowel movements in the past; those who have a history of spinal cord, brain, and, other nerve damage, who cannot control defecation; those who have experienced serious complications, allergic reactions, or adverse events during acupuncture treatment in the past, who cannot cooperate or refuse to Those who tolerate acupuncture treatment
- 2. Patients with other intestinal or anorectal diseases; patients with postoperative complications such as anastomotic leakage, anastomotic bleeding, anastomotic stenosis, and intestinal puncture
- 3. Those who are receiving other acupuncture treatments
- 4. Sacral deformity caused by any reason, those who cannot accurately locate the acupoints
- 5. Patients with serious primary diseases such as cardiovascular, liver, kidney, and hematopoietic system and mental illness;
- 6. Participating in other clinical investigators

#### Previous exclusion criteria:

- 1. Those who have a history of other anorectal surgery or trauma in the past; those who have a history of spinal cord, brain, and, other nerve damage, who cannot control defecation; those who have experienced serious complications, allergic reactions, or adverse events during acupuncture treatment in the past, who cannot cooperate or refuse to Those who tolerate acupuncture treatment
- 2. Patients with other intestinal or anorectal diseases; patients with postoperative complications such as anastomotic leakage, anastomotic bleeding, anastomotic stenosis, and intestinal puncture
- 3. Those who are receiving other acupuncture treatments
- 4. Sacral deformity caused by any reason, those who cannot accurately locate the acupoints
- 5. Patients with serious primary diseases such as cardiovascular, liver, kidney, and hematopoietic system and mental illness;
- 6. Participating in other clinical investigators

#### Date of first enrolment

10/03/2023

#### Date of final enrolment

31/12/2024

## Locations

#### Countries of recruitment

China

## Study participating centre

## Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine

Department of Acupuncture and Moxibustion and Minimally Invasive Oncology No.51, Andingmen Outer Street Chaoyang District Beijing China

100029

# Sponsor information

## Organisation

Third Hospital Affiliated to Beijing University of Chinese Medicine

## Sponsor details

No. 51, Xiaoguan Street Andingmenwai Chaoyang District Beijing China 100029 +86 10-84980751 zydsyec@126.com

## Sponsor type

Hospital/treatment centre

#### Website

http://wjw.beijing.gov.cn

# Funder(s)

## Funder type

Government

#### Funder Name

Beijing Municipal Health Commission

## Alternative Name(s)

, Beijing Municipal Bureau of Health, Commission municipale de la Santé de Beijing, BMHB

## **Funding Body Type**

Government organisation

## **Funding Body Subtype**

Local government

#### Location

China

## **Results and Publications**

## Publication and dissemination plan

Planned publication in a high-impact journal.

## Intention to publish date

01/12/2025

## Individual participant data (IPD) sharing plan

The participant-level data will not be available as it is not covered in the informed consent for participants. The research data will apply the Research Electronic Data Capture (REDCap) for data collection and management.

## IPD sharing plan summary

Not expected to be made available